Transgenomic Inc(NASDAQ:TBIO) announced the earnings results for Fiscal Year 2015 and Q4. The results came in during After-hours on Apr 14, 2016. Earnings per share were $-1.71.
Transgenomic Inc (TBIO) shares turned negative on Mondays trading session with the shares closing down -0.0413 points or -6.56% at a volume of 91,628. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $0.67. The peak price level was also seen at $0.67 while the days lowest was $0.58. Finally the shares closed at $0.5887. The 52-week high of the shares is $3.75 while the 52-week low is $0.49. According to the latest information available, the market cap of the company is $12 M.
Several Insider Transactions has been reported to the SEC. On Jan 11, 2016, Randal J Kirk (10% owner) purchased 4,474,825 shares at $1.00 per share price.
Transgenomic Inc. (Transgenomic) is a global biotechnology company advancing personalized medicine for the detection and treatment of cancer and inherited diseases. The Company is engaged in the provision of its Multiplexed ICE COLD-PCR (MX-ICP) product to the clinical market. The Company operates through two segments: Laboratory Services and Genetic Assays and Platforms. The Company’s laboratories are engaged in genetic testing for cardiology neurology and mitochondrial disorders and for oncology. It has Patient Testing laboratories in New Haven Connecticut and Omaha Nebraska and a Biomarker Identification laboratory in Omaha. Its product offering WAVE System is offered for genetic variation detection in both molecular genetic research and molecular diagnostics. It also distributes bio-instruments produced by other manufacturers (OEM Equipment) through its sales and distribution network. It manufactures and sells consumable products including chromatography columns.